We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Pine Bark Reduces Osteoarthritis and Lowers Joint Pain

By Biotechdaily staff writers
Posted on 08 May 2008
An antioxidant plant extract has been shown to reduce all osteoarthritis (OA) symptoms by 56%, reducing the need for pain medication, and thus improving the gastrointestinal complications resulting from the drugs.

Researchers at the Chieti-Pescara University (Italy) conducted a randomized, double blind, placebo-controlled study of 156 patients with OA of the knee. More...
Patients were administered 100 mg Pycnogenol or placebo, daily for three months. Symptoms were evaluated by WOMAC (Western Ontario and McMaster Universities) index scores and mobility by recording their walking performance on a treadmill. Patients were permitted to continue taking their choice of pain medication provided they recorded every tablet in a diary for later evaluation. Foot volume was measured by the water-displacement method to evaluate foot edema in a randomly selected subgroup of subjects within the two treatment groups. Patients were allowed to use their regular dosage of non-steroid anti-inflammatory drugs (NSAIDs).

The results showed that after three months, scores for pain dropped significantly for the Pycnogenol treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53%. The scores for physical function were reduced by 57% in the Pycnogenol group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol treatment by 56%. Overall wellbeing of patients (emotional function) was significantly enhanced with the Pycnogenol group compared to the placebo group (64% vs. 15%). Results of exercise tests on the treadmill demonstrated an increased performance after three months of Pycnogenol treatment. After the three months, edema decreased in 79% of the Pycnogenol patients and only 1% in placebo-treated patients. NSAID usage dropped by 58% during treatment with Pycnogenol, but only by 1% in treatment with the placebo. The study was published in the April 2008 edition of the journal Phytotherapy Research.

"Pycnogenol seemed a natural fit for this study,” said lead author Gianni Belcaro, M.D. "There are a few main components contributing to the clinical picture of treatment management in osteoarthritis: inflammation causing a progression in the disease, alteration of fatigue resistance and muscular performance - reversing and blocking the vascular problems associated to altered mobility. Theoretically, a treatment with a compound specifically active on all those aspects could be highly effective, which is why we chose Pycnogenol.”

Pycnogenol is a natural antioxidant plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids, and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient.


Related Links:
Chieti-Pescara University

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.